Advertisement

Internal and Emergency Medicine

, Volume 13, Issue 1, pp 69–73 | Cite as

Cost effectiveness of pneumococcal urinary antigen in Emergency Department: a pragmatic real-life study

  • Aurélien DinhEmail author
  • Clara Duran
  • Benjamin Davido
  • Aurore Lagrange
  • Valérie Sivadon-Tardy
  • Frédérique Bouchand
  • Alain Beauchet
  • Jean-Louis Gaillard
  • Sébastien Beaune
  • Jérôme Salomon
  • Julie Grenet
EM - ORIGINAL
  • 262 Downloads

Abstract

Community-acquired pneumonia (CAP) is frequent and can be life-threatening. Streptococcus pneumoniae is the main bacteria involved, and is susceptible to penicillin A. Rapid microbiological diagnosis could then help reduce the antimicrobial spectrum. The pneumococcal urinary antigen (PUA) test is fast and easy to perform, but its impact on antimicrobial prescription and cost-effectiveness in emergency departments (ED) is not well known. We performed a pragmatic real life retrospective study in an adult ED to assess its usefulness: proportion of positive results, impact on antimicrobial prescriptions and cost-effectiveness. Over 3 years (from January 1st 2012 to December 31st 2014), 979 PUA tests were reutilized in our ED among 1224 patients who consulted for CAP; 51 (5.2%) were positive. Among them, 10 led to a modification of the antimicrobial treatment, but only 7 (14.3%) were in accordance with the results. The total cost of a PUA test is 27€. As only 7 PUA tests led to appropriate antimicrobial modification, we deemed that 972 had no impact, and the potential cost savings, if the test had not been used, would have been 26,244 € (972 × 27) during 3 years, that is 8748 € per year. Thus, it seems that the PUA test should not be generally used in the ED considering its low rate of positivity and the difficulties for physicians to adapt antibiotic treatment accordingly. This attitude change in utilization would lead to substantial cost savings.

Keywords

Clinical management Cost effectiveness Infectious diseases Bacterial Community-acquired pneumonia 

Notes

Acknowledgement

Elodie Choisy.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Funding

None.

Statement of human and animal rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ambroise Paré hospital institutional research committee and with the 1964 Helsinki declaration and its later amendments.

Informed consent

For this type of study, formal consent is not required.

References

  1. 1.
    Yealy DM, Auble TE, Stone RA et al (2004) The emergency department community-acquired pneumonia trial: methodology of a quality improvement intervention. Ann Emerg Med 43:770–782. doi: 10.1016/S0196064403010059 CrossRefPubMedGoogle Scholar
  2. 2.
    Niederman MS, McCombs JS, Unger AN et al (1998) The cost of treating community-acquired pneumonia. Clin Ther 20:820–837CrossRefPubMedGoogle Scholar
  3. 3.
    Woodhead M (2002) Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J Suppl 36:20s–27sCrossRefPubMedGoogle Scholar
  4. 4.
    Mandell LA, Wunderink RG, Anzueto A et al (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27–S72CrossRefPubMedGoogle Scholar
  5. 5.
    SPILF (2006) 15th consensus conference about management of lower respiratory tract infections in immunocompetent adults. Med Mal Infect 36:235–244CrossRefGoogle Scholar
  6. 6.
    British Thoracic Society (2015) Annotated BTS Guideline or the management of CAP in adults—Summary of recommendations. https://www.brit-thoracic.org.uk/document-library/clinical-information/pneumonia/adult-pneumonia/annotated-bts-cap-guideline-summary-of-recommendations/. Accessed 10 Nov 2016
  7. 7.
    Sinclair A, Xie X, Teltscher M, Dendukuri N (2013) Systematic review and meta-analysis of a urine-based pneumococcal antigen test for diagnosis of community-acquired pneumonia caused by Streptococcus pneumoniae. J Clin Microbiol 51:2303–2310CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Matta M, Kernéis S, Day N et al (2010) Do clinicians consider the results of the BinaxNOW Streptococcus pneumoniae urinary antigen test when adapting antibiotic regimens for pneumonia patients? Clin Microbiol Infect 16:1389–1393CrossRefPubMedGoogle Scholar
  9. 9.
    Choi MJ, Song JY, Cheong HJ et al (2015) Clinical usefulness of pneumococcal urinary antigen test, stratified by disease severity and serotypes. J Infect Chemother 21:672–679. doi: 10.1016/j.jiac.2015.06.003 CrossRefPubMedGoogle Scholar
  10. 10.
    Andreo F, Prat C, Ruiz-Manzano J et al (2009) Persistence of Streptococcus pneumoniae urinary antigen excretion after pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 28:197–201. doi: 10.1007/s10096-008-0606-3 CrossRefPubMedGoogle Scholar
  11. 11.
    Watanabe H, Uruma T, Tazaki G et al (2015) Clinical factors associated with negative urinary antigen tests implemented for the diagnosis of community-acquired pneumococcal pneumonia in adult patients. Med Princ Pract 24:189–194. doi: 10.1159/000369931 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Mothes A, Léotard S, Nicolle I et al (2016) Community-acquired pneumonia and positive urinary antigen tests: factors associated with targeted antibiotic therapy. Médecine Mal Infect. doi: 10.1016/j.medmal.2016.05.009 Google Scholar
  13. 13.
    Kennedy M, Bates DW, Wright SB et al (2005) Do emergency department blood cultures change practice in patients with pneumonia? Ann Emerg Med 46:393–400CrossRefPubMedGoogle Scholar
  14. 14.
    Ramanujam P, Rathlev NK (2006) Blood cultures do not change management in hospitalized patients with community-acquired pneumonia. Acad Emerg Med 13:740–745CrossRefPubMedGoogle Scholar
  15. 15.
    Schouten JA, Hulscher MEJL, Natsch S et al (2007) Barriers to optimal antibiotic use for community-acquired pneumonia at hospitals: a qualitative study. Qual Saf Health Care 16:143–149CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Blanc V, Mothes A, Smetz A et al (2015) Severe community-acquired pneumonia and positive urinary antigen test for S. pneumoniae: amoxicillin is associated with a favourable outcome. Eur J Clin Microbiol Infect Dis 34:2455–2461. doi: 10.1007/s10096-015-2503-x CrossRefPubMedGoogle Scholar
  17. 17.
    Roger P-M, Risso K, Hyvernat H et al (2010) Urinary pneumococcal or Legionella antigen detection tests and low-spectrum antibiotic therapy for community-acquired pneumonia [Article in French]. Médecine Mal Infect 40:347–351. doi: 10.1016/j.medmal.2010.01.005 CrossRefGoogle Scholar
  18. 18.
    Alere BinaxNOW® Streptococcus pneumoniae. http://www.alere.com/fr/home/product-details/binaxnow-streptococcus-pneumoniae.html. Accessed 10 Nov 2016
  19. 19.
    Falguera M, Ruiz-González A, Schoenenberger JA et al (2010) Prospective, randomised study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalised patients with community-acquired pneumonia. Thorax 65:101–106. doi: 10.1136/thx.2009.118588 CrossRefPubMedGoogle Scholar
  20. 20.
    Sinclair A, Xie X, Dendukuri N (2012) The clinical effectiveness and cost of a pneumococcal urine antigen immunochromatographic test (BinaxNOW Streptococcus pneumoniae) in the diagnosis of community acquired Streptococcus pneumoniae pneumonia in patients admitted to hospital. Report no. 57. http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?ID=32012000049. Accessed 10 Nov 2016
  21. 21.
    Dirou S, Cazanave C (2015) Urine antigen testing: indication and contribution to the treatment of community-acquired pneumonia [Article in French]. Rev Mal Respir 32:845–849. doi: 10.1016/j.rmr.2015.06.004 CrossRefPubMedGoogle Scholar

Copyright information

© SIMI 2016

Authors and Affiliations

  • Aurélien Dinh
    • 1
    Email author
  • Clara Duran
    • 1
  • Benjamin Davido
    • 1
  • Aurore Lagrange
    • 1
  • Valérie Sivadon-Tardy
    • 2
  • Frédérique Bouchand
    • 3
  • Alain Beauchet
    • 4
  • Jean-Louis Gaillard
    • 2
  • Sébastien Beaune
    • 5
  • Jérôme Salomon
    • 1
  • Julie Grenet
    • 5
  1. 1.Infectious Disease UnitUniversity Hospital Raymond Poincaré, AP-HP, Versailles Saint-Quentin UniversityGarchesFrance
  2. 2.Microbiology Laboratory, University Hospital Ambroise ParéAP-HP, Versailles Saint-Quentin UniversityBoulogne-BillancourtFrance
  3. 3.Pharmacy Department, University Hospital Raymond PoincaréAP-HP, Versailles Saint-Quentin UniversityGarchesFrance
  4. 4.IT Department, University Hospital Ambroise ParéAP-HP, Versailles Saint-Quentin UniversityBoulogne-BillancourtFrance
  5. 5.Emergency Department, University Hospital Ambroise ParéAP-HP, Versailles Saint-Quentin UniversityBoulogne-BillancourtFrance

Personalised recommendations